UTHR
United Therapeutics Corporation (UTHR) United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ: UTHR) Q4 2025 Earnings Call dated Feb. 25, 2026 Corporate Participants: Harry Silvers — Head of…
United Therapeutics Corporation (UTHR) United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
United Therapeutics Corporation (UTHR) Leerink Global Healthcare Conference
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Corporate Conference
United Therapeutics Corporation (UTHR) United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
United Therapeutics Corporation (NASDAQ: UTHR) FY 2026 Other Release
United Therapeutics Corporation (UTHR) Sec Form 10K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 10K
United Therapeutics Corporation (UTHR) Sec Form 8K
United Therapeutics Corporation (NASDAQ: UTHR) Sec Form 8K
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Results
United Therapeutics Corporation (NASDAQ: UTHR) Q4 2025 Earnings Release